COMMUNIQUÉ DE PRESSE
News
-
-
-
COMMUNIQUÉ DE PRESSE
LECLANCHE SA annonce une exemption temporaire de l'obligation de publication et de dépôt de son rapport annuel 2024
Leclanché SA annonce une exemption temporaire de l'obligation de publication et de dépôt de son rapport annuel 2024 jusqu'au 30 juin 2025. Mesures en cours pour rétablir fonds propres et financement à long terme -
COMMUNIQUÉ DE PRESSE
LECLANCHE SA announces Temporary Exemption from the Disclosure Obligation in connection with the Publication and the Filing of the 2024 Annual Report
LECLANCHE SA announces Temporary Exemption from Disclosure Obligation regarding 2024 Annual Report. Key measures for positive equity and future plans disclosed -
-
-
COMMUNIQUÉ DE PRESSE
Right Season Announces Appointment of Dr. Kristian Thorlund as Chief Executive Officer and Director
Right Season Investments Corp. appoints Dr. Kristian Thorlund, PhD, as CEO and director, bringing expertise in data science, machine learning, and AI. Previous CEO Tyler Lewis to remain as a director. The Company focuses on innovation and growth opportunities in the Canadian market -
COMMUNIQUÉ DE PRESSE
Onco-Innovations' Inka Health to Launch Global AI-Oncology Consortium to Advance Predictive Cancer Research
Onco-Innovations Limited's subsidiary, Inka Health Corp., launches PROmAI Consortium for AI in oncology to enhance predictive modeling and collaboration among key stakeholders -
COMMUNIQUÉ DE PRESSE
New to The Street Signs MUSQ ETF to Multi-Part Media Series Featuring Long-Form Interviews, Earned Media, and TV Commercials
New to The Street announces partnership with MUSQ ETF for BestETFs.com launch, spotlighting top-performing ETFs in market. Filming starts at NYSE next week -
COMMUNIQUÉ DE PRESSE
New to The Street Signs National Media Agreement with NRx Pharmaceuticals for 12-Part Broadcast Series Across TV, Digital, and Outdoor Platforms
New to The Street partners with NRx Pharmaceuticals, Inc. for multi-platform media campaign showcasing life-saving therapies and biotech innovations. Series airs on Fox Business and Bloomberg
